Table 1 Clinical characteristics and demographics of untreated patients with JDM (n = 20) and healthy controls (n = 5)
From: Increased vascular deposition of oxidized LDL in untreated juvenile dermatomyositis
Healthy controls (n = 5) | JDM (n = 20) | |
|---|---|---|
Age (years), mean ± stdv | 14.4 ± 1.8 | 6.3 ± 2.2 |
Duration of untreated disease at time of biopsy (months), mean ± stdv | NA | 7.6 ± 7.2 |
Race, n (%) | ||
White | 4 (80%) | 20 (100%) |
African American/Black | 1 (20%) | 0 (0%) |
Ethnicity, n (%) | ||
Hispanic | 1 (20%) | 0 (0%) |
Non-Hispanic | 4 (80%) | 20 (100%) |
Clinical Measures of Disease Activity, mean ± stdv | ||
DAS-S (0–9) | NA | 6.2 ± 1.5 |
DAS-M (0–11) | NA | 5.8 ± 2.8 |
DAS-T (0–20) | NA | 12.0 ± 3.7 |
End row capillary loop density (#/1 mm) | NA | 4.73 ± 1.36 |
Lab Values, mean ± stdv | ||
CK (IU/L) | NA | 2218 ± 4497 |
Aldolase (U/L) | NA | 24.5 ± 33.8 |
LDH (IU/L) | NA | 430 ± 217 |
ALT (IU/L) | NA | 126.7 ± 148.3 |
vWF antigen (%) | NA | 158.2 ± 64.8 |
Neopterin (nmol/L) | NA | 19.4 ± 9.5 |
Myositis Specific Antibodies, n (%) | ||
P155/140 | NA | 12 (60%) |
Mi-2 | NA | 4 (20%) |
MJ | NA | 2 (10%) |
Negative | NA | 4 (20%) |
Not available | NA | 1 (5%) |